Biomarker analysis for alectinib and bevacizumab in ALK-positive NSCLC

Biomarker analysis for alectinib and bevacizumab in ALK-positive NSCLC - NLCTG1501-BM

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035180

Enrollment

Registered

2018-12-08

Start date

2015-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALK-positive non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: According to NLCTG1501

Exclusion criteria

Exclusion criteria: According to NLCTG1501

Design outcomes

Primary

Measure	Time frame
To determine the biomarker for the combination therapy of alectinib and bevacizumab in ALK-positive NSCLC.	—

Countries

Japan

Contacts

Public ContactSatoshi Watanabe

Niigata University Graduate School of Medical and Dental Sciences Department of Respiratory Medicine and Infectious Diseases

satoshi7@med.niigata-u.ac.jp025-368-9325

Outcome results